GlobeNewswire
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025
📈
AI Sentiment
Highly Positive
8/10
- Home
- ORIC
as of 12-05-2025 3:46pm EST
$11.05
$0.34
-2.99%
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Chart Type:
Time Range:
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 1.1B | IPO Year: | 2020 |
| Target Price: | $18.78 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.90 - $14.93 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered ORIC Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 75.17%
75.17%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Oric Pharmaceuticals Inc. (ORIC)
Chacko Jacob
Sell
PRESIDENT AND CEO
ORIC Oct 6, 2025
Avg Cost/Share
$12.32
Shares
37,461
Total Value
$461,519.52
Owned After
531,419
SEC Form 4
Piscitelli Dominic
Sell
Chief Financial Officer
ORIC Oct 6, 2025
Avg Cost/Share
$14.52
Shares
11,000
Total Value
$159,718.90
Owned After
48,317
SEC Form 4
Chacko Jacob
Sell
PRESIDENT AND CEO
ORIC Oct 1, 2025
Avg Cost/Share
$12.05
Shares
53,001
Total Value
$638,805.15
Owned After
531,419
SEC Form 4
Chacko Jacob
Sell
PRESIDENT AND CEO
ORIC Sep 30, 2025
Avg Cost/Share
$12.01
Shares
34,538
Total Value
$414,749.57
Owned After
531,419
SEC Form 4
Chacko Jacob
Sell
PRESIDENT AND CEO
ORIC Sep 22, 2025
Avg Cost/Share
$10.80
Shares
125,000
Total Value
$1,349,937.50
Owned After
531,419
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Chacko Jacob | ORIC | PRESIDENT AND CEO | Oct 6, 2025 | Sell | $12.32 | 37,461 | $461,519.52 | 531,419 | |
| Piscitelli Dominic | ORIC | Chief Financial Officer | Oct 6, 2025 | Sell | $14.52 | 11,000 | $159,718.90 | 48,317 | |
| Chacko Jacob | ORIC | PRESIDENT AND CEO | Oct 1, 2025 | Sell | $12.05 | 53,001 | $638,805.15 | 531,419 | |
| Chacko Jacob | ORIC | PRESIDENT AND CEO | Sep 30, 2025 | Sell | $12.01 | 34,538 | $414,749.57 | 531,419 | |
| Chacko Jacob | ORIC | PRESIDENT AND CEO | Sep 22, 2025 | Sell | $10.80 | 125,000 | $1,349,937.50 | 531,419 |
Latest Oric Pharmaceuticals Inc. News
ORIC Breaking Stock News: Dive into ORIC Ticker-Specific Updates for Smart Investing
Compare ORIC vs Leading Stocks
See how ORIC stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ORIC Oric Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.